{"nctId":"NCT00671034","briefTitle":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2008-07-21","type":"ACTUAL"},"conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"count":166,"armGroups":[{"label":"Arm I (combination chemotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: Calaspargase Pegol-mknl","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Other: Laboratory Biomarker Analysis","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Other: Pharmacological Study","Drug: Prednisone","Radiation: Radiation Therapy","Drug: Thioguanine","Drug: Vincristine Sulfate"]},{"label":"Arm II (combination chemotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Drug: Doxorubicin Hydrochloride","Other: Laboratory Biomarker Analysis","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Pegaspargase","Other: Pharmacological Study","Drug: Prednisone","Radiation: Radiation Therapy","Drug: Thioguanine","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"Calaspargase Pegol-mknl","otherNames":["Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl)","Asparlas","Calaspargase Pegol","EZN-2285","SC-PEG E. Coli L-Asparaginase","Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase"]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR- 138719"]},{"name":"Cytarabine","otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"name":"Daunorubicin Hydrochloride","otherNames":["Cerubidin","Cerubidine","Cloridrato de Daunorubicina","Daunoblastin","Daunoblastina","Daunoblastine","Daunomycin Hydrochloride","Daunomycin, hydrochloride","Daunorubicin.HCl","Daunorubicini Hydrochloridum","FI-6339","Ondena","RP-13057","Rubidomycin Hydrochloride","Rubilem"]},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Mercaptopurine","otherNames":["3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","Bw 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"name":"Pegaspargase","otherNames":["L-Asparaginase with Polyethylene Glycol","Oncaspar","Oncaspar-IV","PEG-Asparaginase","PEG-L-Asparaginase","PEG-L-Asparaginase (Enzon - Kyowa Hakko)","PEGLA","Polyethylene Glycol L-Asparaginase","Polyethylene Glycol-L-Asparaginase"]},{"name":"Pharmacological Study","otherNames":[]},{"name":"Prednisone","otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","Perrigo Prednisone","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisone Intensol","Prednisonum","Prednitone","Promifen","Rayos","Servisone","SK-Prednisone"]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]},{"name":"Thioguanine","otherNames":["2-Amino 6MP","2-Amino-1,7-dihydro-6H-purine-6-thione","2-Amino-6-mercaptopurine","2-Amino-6-purinethiol","2-Aminopurin-6-thiol","2-Aminopurine-6(1H)-thione","2-Aminopurine-6-thiol","2-Aminopurine-6-thiol Hemihydrate","2-Mercapto-6-aminopurine","6-Amino-2-mercaptopurine","6-Mercapto-2-aminopurine","6-Mercaptoguanine","6-TG","6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)","BW 5071","Lanvis","Tabloid","Thioguanine Hemihydrate","Thioguanine Hydrate","Tioguanin","Tioguanine","Wellcome U3B","WR-1141","X 27"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must be eligible for and enrolled on AALL08B1 or the successor classification study\n* Patients must have newly diagnosed high-risk B lymphoblastic leukemia (World Health Organization \\[WHO\\] 2008 classification) (also termed B-precursor acute lymphoblastic leukemia)\n* White blood cell (WBC) \\>= 50,000/Î¼L for patients age 1-9 OR any WBC count for patients age 10-30 or for patients treated with prior steroids\n* Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and intrathecal cytarabine; intrathecal chemotherapy with cytarabine is allowed prior to registration for patient convenience; this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture; (Note: the CNS status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment) systemic chemotherapy must begin within 72 hours of this intrathecal therapy\n* Patients receiving prior steroid therapy are eligible for this study; the dose and duration of previous steroid therapy should be carefully documented\n* Pregnancy tests with a negative result must be obtained in all post-menarchal females\n* Lactating females must agree that they will not breastfeed a child while on this study\n\nExclusion Criteria:\n\n* Patients with Down syndrome are excluded from this study\n* Patients with testicular leukemia at diagnosis are excluded from this study\n* Pregnant female patients are excluded from this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)","description":"Mean half-life of plasma asparaginase during consolidation and Induction; half-life is defined as the time taken for drug concentration to decrease by half.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"415.8","spread":"148.51"},{"groupId":"OG001","value":"355.9","spread":"133.0"},{"groupId":"OG002","value":"117.2","spread":"49.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"305.1","spread":"98.33"},{"groupId":"OG001","value":"321.5","spread":"118.22"},{"groupId":"OG002","value":"126.9","spread":"50.51"}]}]}]},{"type":"SECONDARY","title":"Pharmacodynamics (PD)","description":"Plasma Asparaginase Concentration During consolidation and induction.","paramType":"MEDIAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"575.9","spread":"233.91"},{"groupId":"OG001","value":"617.2","spread":"321.41"},{"groupId":"OG002","value":"562.1","spread":"296.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271.6","spread":"118.17"},{"groupId":"OG001","value":"339.6","spread":"126.83"},{"groupId":"OG002","value":"72.8","spread":"47.94"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction","description":"Percentage of participants with Negative MRD (MRD\\<0.01%).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"72.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Remission at the End of Induction","description":"Complete Remission (CR) rate; where CR is defined as M1 marrow (\\< 5% lymphoblasts in the bone marrow)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"97.6","spread":null},{"groupId":"OG002","value":"94.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Event-free Survival (EFS)","description":"Percentage of participants who were event free. Event Free Probability defined as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignant neoplasm, remission death) or date of last contact for subjects who are event-free.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.35","spread":null},{"groupId":"OG001","value":"80.8","spread":null},{"groupId":"OG002","value":"79.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Asparaginase Level","description":"The proportion of patients with an asparaginase level of at least 0.1 IU/mL and the proportion with at least 0.4 IU/mL on Days 4, 15, 22 and 29 of Induction compared to Oncaspar","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"95.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"93.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"14.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null},{"groupId":"OG001","value":"27.5","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma and CSF Concentrations of Asparagine in ug/ml","description":"The plasma and CSF concentrations of asparagine in ug/ml after administration of EZN-2285 compared to Oncaspar.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.108"},{"groupId":"OG001","value":"0.19","spread":"0.086"},{"groupId":"OG002","value":"0.26","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.784"},{"groupId":"OG001","value":"0.25","spread":"1.231"},{"groupId":"OG002","value":"0.83","spread":"2.195"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity","description":"Number of Patients with Positive Immunogenicity tests","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicities During Post Induction Intensification Therapy (All Grades)","description":"The calculation of AE incidence will be based on the number of patients per AE category. For each patient who has multiple AEs classified to the same category, that patient will be tabulated under the worst toxicity grade for that AE category. The incidence of AEs will be tabulated by treatment arm and by organ class. Special attention will be paid to hypersensitivity, pancreatitis, coagulopathy, infection, neurologic dysfunction and thromboembolic events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.4","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"45.5","spread":null},{"groupId":"OG002","value":"30.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"38.5","spread":null},{"groupId":"OG002","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"27.6","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"42.4","spread":null},{"groupId":"OG002","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"61.5","spread":null},{"groupId":"OG002","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"44.8","spread":null},{"groupId":"OG002","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"7.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"9.1","spread":null},{"groupId":"OG002","value":"7.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":null},{"groupId":"OG001","value":"26.9","spread":null},{"groupId":"OG002","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"6.9","spread":null},{"groupId":"OG002","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Relationship Between PK and Presence of Antibodies","description":"Patients with presence of Antibodies.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":54,"n":69},"commonTop":["Neutrophil count decreased","Febrile neutropenia","Alanine aminotransferase increased","Platelet count decreased","Infections and infestations - Other, specify"]}}}